2023-506509-21-00招募中1 期
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 47
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Sujata Sankar
Scientific
Verge Genomics
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of ACE-1334 to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy in Participants with Systemic Sclerosis with and without Interstitial Lung DiseaseSystemic sclerosis (SSc), a rare connective tissue disorder characterized by fibrosis, inflammation, and microvascular injury with heterogeneous presentationsInterstitial lung disease (ILD), a common manifestation of SSc that tends to occur early in the course of the disease.MedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859MedDRA version: 21.0Level: PTClassification code 10037383Term: Pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 21.1Level: PTClassification code 10022611Term: Interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: PTClassification code 10042954Term: Systemic sclerosis pulmonarySystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 21.0Level: LLTClassification code 10025109Term: Lung involvement in systemic sclerosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-001004-15-ITACCELERON PHARMA INC.210
尚未招募
不适用
Phase I/Ib, open-label, multiple ascending dose, first-in-human study, to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of INT-1B3 in patients with advanced solid tumorsNL-OMON52968InteRNA Technologies B.V.40
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-FRAgenus Inc.85
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 21.1Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-PLAgenus Inc.200
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864EUCTR2017-000556-26-ESAgenus Inc.150